Other recently-published results indicate that circulating GDF15 levels are elevated in patients hospitalized with COVID-19, and higher concentrations are associated with SARS-CoV-2 viremia, hypoxemia, and worse outcomes. This evidence concerns the gene GDF15 and COVID-19.